To address these issues, in this study we evaluated the anti-melanoma activity in vitro and in vivo of two- or three-drug associations using TRAIL, the MEK 1/2 inhibitor AZD6244/Selumetinib, which has significant clinical activity in melanoma,23 and the PI3K/mTOR inhibitor BEZ235, currently in clinical trials in different solid tumors, including melanoma (source www.clinicaltrials.gov). The gene discussed is MTOR; the disease is melanoma.